The ultimate objective of the research projects in this program project application is to improve the therapeutic results for patients with leukemia and lymphoma. To achieve this objective, results of laboratory studies will be used to provide the basis for development of new treatment approaches in the clinic. At the same time, tumor samples from patients at diagnosis and/or relapse and normal lymphocytes and other cells from patients enrolled on clinical trials are studied to assess the responses to new treatments. As a results, the clinical projects in particular require research resources which extend beyond direct patient care and clinical laboratory functions. Without clinical research support provided in this Core it would not be possible to coordinate the proper collection of multiple research specimens from hundreds of patients/year, as well as th timely follow up of patients enrolled on research studies. Equally important for the success of the project is the collaboration of individuals in this core with staff from the biostatistic Core, who provide a quality control system for specimen tracking, computerized data entry, quality control of data as well as assist in the design and analysis of clinical research protocols. The purpose of the Clinical Research Support Core is to provide the following services that will be utilized by all of the research projects. 1. To collect research specimens and coordinate patient follow-up at DFCI and affiliated hospitals. 2. Act as liaison with outside physician and hospitals to coordinate the collection of research specimens and follow-up data. 3. To ensure that study parameters are followed, confirm eligibility and patient registration. 4. Ensure that study parameters are followed, confirm eligibility and patient registration. 4. Ensure accuracy of submitted data from outside sources. 5. To provide data management for the collection of individual patient information.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA066996-04
Application #
6103053
Study Section
Project Start
1999-04-20
Project End
2000-03-31
Budget Start
1998-10-01
Budget End
1999-09-30
Support Year
4
Fiscal Year
1999
Total Cost
Indirect Cost
Name
Dana-Farber Cancer Institute
Department
Type
DUNS #
149617367
City
Boston
State
MA
Country
United States
Zip Code
02215
Patel, Sanjay S; Kuo, Frank C; Gibson, Christopher J et al. (2018) High NPM1-mutant allele burden at diagnosis predicts unfavorable outcomes in de novo AML. Blood 131:2816-2825
Montero, Joan; Letai, Antony (2018) Why do BCL-2 inhibitors work and where should we use them in the clinic? Cell Death Differ 25:56-64
DeAngelo, Daniel J; Brunner, Andrew M; Werner, Lillian et al. (2018) A phase I study of lenalidomide plus chemotherapy with mitoxantrone, etoposide, and cytarabine for the reinduction of patients with acute myeloid leukemia. Am J Hematol 93:254-261
Fink, Emma C; McConkey, Marie; Adams, Dylan N et al. (2018) CrbnI391V is sufficient to confer in vivo sensitivity to thalidomide and its derivatives in mice. Blood 132:1535-1544
Wroblewski, Mark; Scheller-Wendorff, Marina; Udonta, Florian et al. (2018) BET-inhibition by JQ1 promotes proliferation and self-renewal capacity of hematopoietic stem cells. Haematologica 103:939-948
Konopleva, Marina; Letai, Anthony (2018) BCL-2 inhibition in AML: an unexpected bonus? Blood 132:1007-1012
Donovan, Katherine A; An, Jian; Nowak, Rados?aw P et al. (2018) Thalidomide promotes degradation of SALL4, a transcription factor implicated in Duane Radial Ray syndrome. Elife 7:
Lee, J Scott; Roberts, Andrew; Juarez, Dennis et al. (2018) Statins enhance efficacy of venetoclax in blood cancers. Sci Transl Med 10:
Liu, Bee Hui; Jobichen, Chacko; Chia, C S Brian et al. (2018) Targeting cancer addiction for SALL4 by shifting its transcriptome with a pharmacologic peptide. Proc Natl Acad Sci U S A 115:E7119-E7128
Kahn, Josephine D; Miller, Peter G; Silver, Alexander J et al. (2018) PPM1D-truncating mutations confer resistance to chemotherapy and sensitivity to PPM1D inhibition in hematopoietic cells. Blood 132:1095-1105

Showing the most recent 10 out of 376 publications